TY - JOUR
T1 - Anti-integrin αvβ6 Autoantibodies are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity
AU - Bloemen, Hannah
AU - Livanos, Alexandra E.
AU - Martins, Adrielly
AU - Dean, Richard
AU - Bravo, Ana Catarina
AU - Bourgonje, Arno R.
AU - Tankelevich, Michael
AU - Herb, Jake
AU - Cho, Judy
AU - Santos, André Anastácio
AU - Rodrigues, Cecília M.P.
AU - Petralia, Francesca
AU - Colombel, Jean Frederic
AU - Bowlus, Christopher L.
AU - Schiano, Thomas
AU - Torres, Joana
AU - Levy, Cynthia
AU - Mehandru, Saurabh
N1 - Publisher Copyright:
© 2024 AGA Institute
PY - 2024
Y1 - 2024
N2 - Background & Aims: Anti-integrin αvβ6 autoantibodies (anti-αvβ6) are found in more than 50% of individuals with ulcerative colitis (UC). We aimed to determine the prevalence of anti-αvβ6 in patients with primary sclerosing cholangitis (PSC) and their association with liver disease severity. Methods: Four cohorts of pre-liver transplant patients with PSC were recruited. Patients with inflammatory bowel disease (IBD) and healthy controls (HCs) served as comparators. Total IgG and anti-αvβ6 levels were measured using enzyme-linked immunosorbent assay. Olink inflammation panel was run on a subset of samples. Multivariable linear regression analysis was performed to assess the association between anti-αvβ6 and indices of liver disease severity. Results: A total of 137 patients with PSC (including 76 with PSC-UC, 33 with PSC-Crohn's disease (CD), and 28 with PSC alone) and 160 controls (including 91 with IBD and 69 HCs) were enrolled. Anti-αvβ6 levels were significantly higher in PSC-UC and PSC-CD compared with PSC alone (P < .0001 and P < .003) and HCs (P < .0001 and P < .0001). However, anti-αvβ6 levels in PSC alone were not increased compared with HCs. In patients with PSC-IBD, anti-αvβ6 levels correlated with markers of liver disease severity, including alkaline phosphatase level (r = 0.32; P = .004), the revised Mayo PSC risk score (r = 0.25; P = .02), and liver stiffness measurement (r = 0.43; P = .008) after adjusting for age, gender, race/ethnicity, and IBD subtype. Additionally, anti-αvβ6 levels were associated with markers of systemic inflammation and tissue remodeling. Conclusion: Anti-αvβ6 autoantibodies identify a subset of patients with PSC with concomitant IBD.
AB - Background & Aims: Anti-integrin αvβ6 autoantibodies (anti-αvβ6) are found in more than 50% of individuals with ulcerative colitis (UC). We aimed to determine the prevalence of anti-αvβ6 in patients with primary sclerosing cholangitis (PSC) and their association with liver disease severity. Methods: Four cohorts of pre-liver transplant patients with PSC were recruited. Patients with inflammatory bowel disease (IBD) and healthy controls (HCs) served as comparators. Total IgG and anti-αvβ6 levels were measured using enzyme-linked immunosorbent assay. Olink inflammation panel was run on a subset of samples. Multivariable linear regression analysis was performed to assess the association between anti-αvβ6 and indices of liver disease severity. Results: A total of 137 patients with PSC (including 76 with PSC-UC, 33 with PSC-Crohn's disease (CD), and 28 with PSC alone) and 160 controls (including 91 with IBD and 69 HCs) were enrolled. Anti-αvβ6 levels were significantly higher in PSC-UC and PSC-CD compared with PSC alone (P < .0001 and P < .003) and HCs (P < .0001 and P < .0001). However, anti-αvβ6 levels in PSC alone were not increased compared with HCs. In patients with PSC-IBD, anti-αvβ6 levels correlated with markers of liver disease severity, including alkaline phosphatase level (r = 0.32; P = .004), the revised Mayo PSC risk score (r = 0.25; P = .02), and liver stiffness measurement (r = 0.43; P = .008) after adjusting for age, gender, race/ethnicity, and IBD subtype. Additionally, anti-αvβ6 levels were associated with markers of systemic inflammation and tissue remodeling. Conclusion: Anti-αvβ6 autoantibodies identify a subset of patients with PSC with concomitant IBD.
KW - Autoantibodies
KW - Integrin αvβ6
KW - Primary Sclerosing Cholangitis
KW - Prognosis
KW - Ulcerative Colitis
UR - http://www.scopus.com/inward/record.url?scp=85211250296&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2024.10.005
DO - 10.1016/j.cgh.2024.10.005
M3 - Article
C2 - 39490950
AN - SCOPUS:85211250296
SN - 1542-3565
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
ER -